19900 MACARTHUR BLVD., IRVINE, CA
Reports First Quarter 2026 Financial Results and Recent Business Highlights
Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
Eledon Pharmaceuticals Enters Exchange Agreement for 4.2M Shares
Announces Recent Business Highlights and Third Quarter 2025 Financial Results
Eledon Pharmaceuticals Enters Underwriting Agreement for Public Offering
Eledon's Phase 2 BESTOW Trial Results for Tegoprubart at ASN Kidney Week 2025
Reports Second Quarter 2025 Operating and Financial Results
Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Q1
FY 2025
Q3
Q2
Amended Annual Report
Amended Quarterly Report
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
PRE 14A
Definitive Proxy Statement
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload